Non-invasive biomarkers and FIB-4, APRI scoring system to rule out advanced liver injury

Chronic liver Injury (CLI) and its end-stages, cirrhosis, hepatocellular carcinoma (HCC), are leading causes of morbidity mortality worldwide with enormous socioeconomic costs. Clinical management chronic injury is dependent on the extent fibrosis. Liver biopsy, gold standard, still recommended in most patients. disease diagnosis can generally be made using a carefully obtained history, physical examination, few laboratory tests. Initial testing should include aspartate aminotransferase (AST), alanine (ALT), alkaline phosphatase (ALP), total bilirubin. Biomarkers being developed as alternatives to biopsy for predicting fibrosis, Cirrhosis HCC patients injury. An intensive research non-invasive alternatives. A simple, reproducible, low-cost, tool that follow evolution overtime would beneficial physician desired by The aim this review summarize Non-Invasive addition score systems like FIB-4 (Aspartate Platelet Ratio Index) APRI assessment Fibrosis, HCC.